Development of a low-dose monthly injectable contraceptive system: I. Choice of compounds, dose and administration route.
A low-dose combined estrogen-progestogen sustained release system has been developed. The control of crystal size of the steroids produced sustained dissolution in vitro and in vivo. A dose-response experiment carried out in healthy women indicated that 10 mg of norethisterone (NET) with 1 mg of ethinylestradiol (EE2) when given by intramuscular injection maintained NET serum levels above 1 ng/ml for at least 25 days. The system is considered suitable for one month contraceptive protection.
D000328:Adult; D003271:Contraceptive Agents, Female / Q000008:administration & dosage*; D003692:Delayed-Action Preparations; D004305:Dose-Response Relationship, Drug; D004997:Ethinyl Estradiol / Q000008:administration & dosage*; D005260:Female; D006801:Humans; D007273:Injections, Intramuscular; D007279:Injections, Subcutaneous; D009640:Norethindrone / Q000008:administration & dosage*
D003271:Contraceptive Agents, Female; D003692:Delayed-Action Preparations; D004997:Ethinyl Estradiol; D009640:Norethindrone